Search

Your search keyword '"Lamprecht, Misty"' showing total 23 results
Start Over Author "Lamprecht, Misty"
23 results on '"Lamprecht, Misty"'

1. Developing Practice Guidelines for Preparation and Infusion of Cellular Therapy Products

Author

Rimkus, Chris, primary, Rumsey, Ashley, additional, Miles, Jessica, additional, Skinner, Michelle, additional, Stiles, Jessica, additional, Sheldon, Elizabeth, additional, Eunson, Thomas, additional, Puti, Arlen, additional, van Lier, Mrs. Adelaide, additional, West, Mrs. Nicole, additional, McEntee, Nicole, additional, Waldrup, Mrs. Krystal, additional, Hente, Monica, additional, Blacken, Robyn, additional, Roth, Emily, additional, Burke, Ryan, additional, Stromerson, Jessica, additional, Park, Soyoung, additional, Caprio, Meredith, additional, Lamprecht, Misty, additional, Stark, Karley, additional, Leiker, Britany, additional, Austin, Nancy, additional, Guillory, Margie, additional, Vanregenmorter, Lynn, additional, Caldon, Kate L, additional, Baus, Allison, additional, Cooke, Sara, additional, Norkunas, Kathy, additional, MacKrell, Mary, additional, Quigley, Suzanne, additional, Walford, Lauren, additional, and Elledge, Carole, additional

Published
2024
Full Text
View/download PDF

5. Cytopenias after Chimeric Antigen Receptor T-Cells (CAR-T) Infusion; Patterns and Outcomes

Author

Schaefer, Andrew, primary, Saygin, Caner, additional, Maakaron, Joseph, additional, Hoelscher, Tara, additional, Purdin, Zebulun, additional, Robinson, Jacquela, additional, Lamprecht, Misty, additional, Penza, Sam, additional, Brammer, Jonathan E., additional, Efebera, Yvonne A., additional, Benson, Don M, additional, Vasu, Sumithira, additional, Mims, Alice, additional, Blaser, Bradley, additional, Choe, Hannah, additional, Larkin, Karilyn, additional, Long, Meixiao, additional, Rosko, Ashley, additional, Grieselhuber, Nicole, additional, Wall, Sarah, additional, Jaglowski, Samantha, additional, and William, Basem M., additional

Published
2019
Full Text
View/download PDF

6. Pharmacokinetic-Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant

Author

Cho, Yu Kyoung, primary, Irby, Donald J., additional, Li, Junan, additional, Sborov, Douglas W., additional, Mould, Diane R., additional, Badawi, Mohamed, additional, Dauki, Anees, additional, Lamprecht, Misty, additional, Rosko, Ashley E., additional, Fernandez, Soledad, additional, Hade, Erinn M., additional, Hofmeister, Craig C., additional, Poi, Ming, additional, and Phelps, Mitch A., additional

Published
2018
Full Text
View/download PDF

7. Detection of toxigenic Clostridium difficile colonization in patients admitted to the hospital for chemotherapy or haematopoietic cell transplantation

Author

Vaughn, John L., primary, Balada-Llasat, Joan-Miquel, additional, Lamprecht, Misty, additional, Huang, Ying, additional, Anghelina, Mirela, additional, El Boghdadly, Zeinab, additional, Bishop-Hill, Karen, additional, Childs, Rachel, additional, Pancholi, Preeti, additional, and Andritsos, Leslie A., additional

Published
2018
Full Text
View/download PDF

8. G-CSF improves safety when you start the day after autologous transplant in multiple myeloma

Author

Sborov, Douglas W., primary, Cho, Yu Kyoung, additional, Cottini, Francesca, additional, Hade, Erinn M., additional, Lamprecht, Misty, additional, Tackett, Karen, additional, Sharma, Nidhi, additional, Williams, Nita, additional, Li, Junan, additional, Devine, Steven, additional, Poi, Ming, additional, Phelps, Mitch A., additional, and Hofmeister, Craig C., additional

Published
2017
Full Text
View/download PDF

12. CAR T-Cell Therapy: Update on the state of the science.

Author

Lamprecht, Misty and Dansereau, Colleen

Subjects
*LYMPHOBLASTIC leukemia treatment, *CELL receptors, *BIOMEDICAL engineering, *DRUG administration, *IMMUNOTHERAPY, *LEUKAPHERESIS, *T cells, *CONTINUING education units, *THERAPEUTICS
Abstract

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy leverages the power of the patient's own immune system by serving as a bridge to connect genetically modified T cells to the surface antigens of tumor cells based on targeted ligands. Clinical trials have demonstrated compelling overall response and survival rates in individuals with B-cell malignancies. The current approved agents target CD19, an antigen commonly overexpressed in B-cell hematologic and other malignancies. OBJECTIVES: This article provides information on the current state of the science related to commercially available CAR T-cell products and examines how CAR T-cell science is evolving. METHODS: An overview of pathophysiology, indications, and nursing implications of the currently approved CAR T-cell agents is presented. Future directions for CAR T-cell development and treatment indications are discussed. FINDINGS: Tisagenlecleucel (Kymriah®) and axicabtagene ciloleucel (Yescarta®) received approval in 2017 for the treatment of B-cell precursor acute lymphoblastic leukemia in pediatric and young adult patients, and relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in adult patients, respectively. Additional indications have since been approved, and new agents are in development. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

18. 2-Hour Cryotherapy Effectively Reduces Severe Mucositis Associated with High-Dose Melphalan Followed By Stem Cell Rescue: Results from a Randomized Trial

Author

Sborov, Douglas W., primary, Lamprecht, Misty, additional, Benson, Don, additional, Tackett, Karen, additional, Efebera, Yvonne A, additional, Ashley, Rosko E, additional, Devine, Steven M., additional, Poi, Ming, additional, Phelps, Mitch A., additional, and Hofmeister, Craig C, additional

Published
2014
Full Text
View/download PDF

21. From Unit Based to Population Focused

Author

Catania, Kimberly, primary, Askew, Taletha, additional, Birkhimer, Danette, additional, Courtney, Laurel, additional, Hanes, Deborah, additional, Lamprecht, Misty, additional, Rettig, Amy, additional, and Vendlinski, Susanne, additional

Published
2012
Full Text
View/download PDF

22. Toxigenic Clostridium DifficileColonization in Patients with Hematologic Malignancies Admitted to the Hospital for Chemotherapy or Hematopoietic Cell Transplantation

Author

Vaughn, John L, Lamprecht, Misty, Huang, Ying, Anghelina, Mirela, Balada-Llasat, Joan-Miquel, El Boghdadly, Zeinab, Childs, Rachel, Pancholi, Preeti, and Andritsos, Leslie A

Abstract

Background: Clostridium difficile(CD) is an important cause of infectious diarrhea in patients with hematologic malignancies (HM) admitted to the hospital for chemotherapy or hematopoietic cell transplantation (HM-HCT patients). These patients are at increased risk of developing Clostridium difficileinfection (CDI) compared to non-oncology patients, and they are more likely to suffer adverse outcomes from the infection. Asymptomatic colonization of patients with CD is known to precede infection. However, the reported prevalence of asymptomatic colonization varies widely between studies. The primary objective of this study was to define the prevalence of toxigenic CD colonization in patients with hematologic malignancies who were admitted to the hospital for scheduled chemotherapy or hematopoietic cell transplantation (HCT). The secondary objective was to determine what microbiology tests are accurate in detecting CD colonization compared to the gold standard of toxigenic culture.

Published
2017
Full Text
View/download PDF

23. Cytopenias after Chimeric Antigen Receptor T-Cells (CAR-T) Infusion; Patterns and Outcomes.

Author

Shaefer, Andrew, Saygin, Caner, Maakaron, Joseph, Hoelscher, Tara, Purdin, Zebulun, Robinson, Jacquela, Lamprecht, Misty, Penza, Sam, Brammer, Jonathan E., Efebera, Yvonne A., Benson, Don M, Vasu, Sumithira, Mims, Alice, Blaser, Bradley, Choe, Hannah, Larkin, Karilyn, Long, Meixiao, Rosko, Ashley, Grieselhuber, Nicole, and Wall, Sarah

Subjects
*T cells, *CHIMERIC antigen receptors, *CANCER immunotherapy, *CANCER chemotherapy, *STEM cell treatment, *DRUG approval
Abstract

Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have poor treatment outcomes when treated with traditional chemoimmunotherapy. Superior outcomes have been observed with the 2 CAR-T cell products approved by the US FDA; tisagenlecleucel (CTL109) and axicabtagene ciloleucel (Axi-cel) with 12 months overall survival rates of 49% and 59% respectively. The 2 major acute toxicities of these therapies are cytokine release syndrome (CRS) and neurotoxicity. The incidence of grade 3 or higher neutropenia, anemia, and thrombocytopenia was 78%, 43%, and 38% in patients treated with axi-cel. Little is known regarding the patterns and outcomes of these cytopenias. Here we present our preliminary experience on the patterns and outcomes of cytopenias in 32 patients who received commercially-available CAR-T cell therapy at our institution. We retrospectively reviewed all DLBCL patients receiving either CTL109 or axi-cel between January and September 2018 at our institution. All patients received a conditioning regimen of low-dose cyclophosphamide and fludarabine, followed by CAR-T infusion. Persistent cytopenias were defined as incomplete absolute neutrophil count (<1 × 109/L), Hb (<12 g/dL) or platelet count (<100 × 109/L) recovery after day 28 of CAR-T cell infusion. Treatment response was assessed with PET-CT imaging and classified according to International Working Group Criteria. The median age of patients was 59 years (range, 23-80); 63% were male, 4 patients (13%) received CTL109 and 28 (87%) received axi-cel. Twenty-two patients (69%) had a 3 month follow up imaging for assessment of response, of whom 7 patients (32%) achieved complete response (CR), 6 patients (27%) achieved partial response (PR), and 9 patients (41%) had progressive disease (PD). Persistent neutropenia was observed in 3 patients (9%), while persistent thrombocytopenia was seen in 21 cases (65%) and persistent anemia was the most common with a frequency of 72% (23/32 cases). Median time to neutrophil, platelet and Hb recoveries were 11 days (range, 5-218 days), 59.5 days (range, 4-241 days), and 76 days (range, 0-218 days), respectively. Filgrastim was used in 15 (47%) patients to facilitate neutrophil recovery. Twenty-three patients (72%) experienced neurotoxicity, of whom 11 (34%) had grade 3-4 toxicity. The frequency of CRS was 94% (29 out of 32 patients), with grade 3-4 CRS observed in 4 cases (12.5%). We observed no significant association between CRS and persistent cytopenias. In our preliminary series of 32 patients, persistent anemia and thrombocytopenia were more common than neutropenia after CAR-T cell therapy. However, most of these patients required growth factor support for neutrophil recovery. Longer duration of follow up is necessary to determine the impact of persistent cytopenias on outcomes and survival after CAR-T cell therapy. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results